



Endoscopic Submucosal Dissection for Early Gastric Cancer in Elderly vs. Non-Elderly Patients: A Systematic Review and Meta-Analysis

Jiting Zhao¹, Zhen Sun¹, Junwei Liang¹, Song Guo¹ and Di Huang^{2*}

¹ Department of Spleen and Stomach Disease, Shandong University of Traditional Chinese Medicine Affiliated Hospital, Jinan, China, ² Shandong University of Traditional Chinese Medicine, Jinan, China

Objective: This study aimed to review the applicability and complications rate associated with endoscopic submucosal dissection (ESD) for early gastric cancer in elderly patients.

OPEN ACCESS

Edited by:

Alberto Biondi, Agostino Gemelli University Polyclinic (IRCCS), Italy

Reviewed by:

Savio George Barreto, Flinders Medical Centre, Australia Thin Thin Win, International Medical University, Malaysia Katharina Beyer, Charité University Medicine Berlin, Germany

> *Correspondence: Di Huang huangdi198905@163.com

Specialty section:

This article was submitted to Gastrointestinal Cancers, a section of the journal Frontiers in Oncology

Received: 01 June 2021 Accepted: 21 December 2021 Published: 13 January 2022

Citation:

Zhao J, Sun Z, Liang J, Guo S and Huang D (2022) Endoscopic Submucosal Dissection for Early Gastric Cancer in Elderly vs. Non-Elderly Patients: A Systematic Review and Meta-Analysis. Front. Oncol. 11:718684. doi: 10.3389/fonc.2021.718684 **Methods:** Databases of PubMed, Embase, CENTRAL, and ScienceDirect were searched till 15th April 2021. All types of studies comparing ESD in the elderly vs non-elderly were included. Subgroup analysis was conducted for the following groups: \geq 80 years vs <80 years, \geq 75 years vs < 75 years, and \geq 65 years vs <65 years.

Results: 17 studies were included. Meta-analysis indicated no statistically significant difference in the en-bloc resection rates (OR: 0.92 95% CI: 0.68, 1.26 $I^2 = 8\%$ p=0.62) and histological complete resection rates (OR: 0.93 95% CI: 0.75, 1.15 $I^2 = 26\%$ p=0.50) between elderly and non-elderly patients. The results were non-significant even on subgroup analysis. Overall, we found a non-significant but a tendency of increased perforation rates in the elderly as compared to non-elderly patients (OR: 1.22 95% CI: 0.99, 1.52 $I^2 = 0\%$ p=0.06). However, there was a significantly increased risk of perforation in elderly patients aged ≥80 years as compared to patients <80 years (OR: 1.50 95% CI: 1.00, 2.24 $I^2 = 3\%$ p=0.05). Bleeding rates were not different in the two groups (OR: 1.07 95% CI: 0.87, 1.32 $I^2 = 19\%$ p=0.52). Pooled analysis indicated a statistically significantly increased risk of pneumonia in elderly patients (OR: 2.52 95% CI: 1.72, 3.70 $I^2 = 7\%$ p<0.00001). Length of hospital stay was reported only by five studies. Meta-analysis indicated no significant difference between the two study groups (MD: 0.67 95% CI: -0.14, 1.48 $I^2 = 83\%$ p=0.10).

Conclusion: En-bloc and histological complete resection rates do not differ between elderly and non-elderly patients undergoing ESD for early gastric cancer. Elderly patients have a small tendency of increased risk of perforation with significantly increased rates in the super-elderly (≥80 years of age). The risk of pneumonia is significantly higher in elderly patients but the rates of bleeding do not differ. The certainty of evidence is "very low" and there is a need for high-quality studies taking into account confounding factors to enhance the quality of evidence.

Keywords: gastric cancer, surgery, geriatric, complications, endoscopy

INTRODUCTION

Over the years, there has been a gradual improvement in life expectancy owing to significant advances in healthcare and accessibility of medical resources worldwide. Almost every country in the world is experiencing an increase in the proportion of elderly individuals in their overall population. According to the 2019 United Nations report, around 703 million persons were above the age of 65 years in 2019 and this figure is expected to double to 1.5 billion by 2050 (1). As healthcare professionals are expected to face an increased load of elderly patients in their practice, the efficacy and safety of different surgical procedures must be optimally understood for these individuals.

Gastric cancer is one of the leading causes of death, especially in older adults. It is estimated to the 5th most common cancer and third most lethal malignancy causing around 783,000 deaths in 2018 alone (2). Epidemiological data indicate that gastric cancer is highly prevalent in regions of East Asia, eastern Europe, and Russia (3). With a rise in the incidence of esophagogastroduodenoscopy in elderly patients, a large number of patients with early gastric cancer are frequently detected in these regions (4). Over the last few decades, endoscopic submucosal dissection (ESD), a minimally invasive technique, has become the standard treatment modality for the management of early gastric cancer (5). As gastric cancer in the early stages is confined to the superficial layers of the mucosa, endoscopic dissection can be safely performed to excise the entire lesion for histopathological evaluation, thereby minimizing patient morbidity and mortality (6). The procedure consists of an initial injection of fluid in the submucosal layer to elevate the lesion. This is followed by a circular incision on the surrounding mucosa of the lesion and subsequent dissection of the submucosal layer to completely elevate the tumor (7). Studies have demonstrated that ESD is safe and feasible in patients with early gastric cancer with comparable long-term survival as compared to gastrectomy (8).

Since elderly patients have poor overall health status along with several other comorbidities, ESD is an attractive treatment option in these patients as compared to gastrectomy to minimize operative morbidity. However, it is not very clear if ESD per-se safe and feasible in this group of patients. It is important to know if the resection rates in elderly patients are comparable to nonelderly patients to recommend it as a treatment option. Furthermore, clinicians should have a clear understanding of the risk of complications with ESD in this cohort so that appropriate preventive measures can be taken to reduce them. To the best of our knowledge, to date, only one meta-analysis published in 2015 has assessed outcomes of ESD in the elderly, but it could include only nine studies (9). The review was also unable to differentiate outcomes based on various definitions of elderly (≥65 years, ≥75 years, or \geq 80 years). Further, with the publication of several recent studies (10-12), there is a need for updated evidence on the applicability and safety of ESD in elderly patients. In this context, the current study was designed to compare resection rates, complication rates, and length of hospital stay between elderly and non-elderly patients undergoing ESD for early gastric cancer.

MATERIAL AND METHODS

Search Strategy

The PRISMA statement (Preferred Reporting Items for Systematic Reviews and Meta-analyses) was followed during the conduct of this review (13). We searched for eligible studies electronically on the databases of PubMed, Embase, CENTRAL, and ScienceDirect. Two authors carried out the literature search independent of each other. The lower time limit of the search was from the inception of the databases. The last search was conducted on 15th April 2021. Keywords used in various combinations were: "elderly", "aged", "older", "geriatric", "endoscopic submucosal dissection", and "gastric cancer". Details are provided in Supplementary Table 1. The results of each database were reviewed by their titles and abstracts and articles relevant to the review were segregated. The two authors evaluated the full text of these articles for final inclusion in the study. Any disagreements in the selection process were resolved by discussion. Finally, we also performed a hand-search of the bibliography of studies meeting the inclusion criteria and previous reviews on the topic for any missed references.

Eligibility Criteria

The inclusion criteria of the review were outlined based on the PICO (Population, Intervention, Comparison, Outcome) guideline. We included studies which were:

- 1. All studies conducted on a *Population* of adult early gastric cancer patients undergoing ESD.
- 2. had a group (*Intervention*) of elderly patients (age group defined as per the study).
- 3. being *Compared* with a group of non-elderly patients.
- 4. reporting one of the following *Outcomes*:- en-bloc dissection rate, histological complete resection rates, length of hospital stay, or complications.

Exclusion criteria for the review were are follows: 1) Studies not on patients with early gastric cancer 2) Studies not defining "elderly" population 3) Single arm studies not comparing outcomes with non-elderly group 4) Non-English language studies, case reports, and review articles. 5) Studies reporting duplicate data. In case of two or more studies were from the same healthcare setup, we included the article with the largest sample size.

Data Extraction and Quality Assessment

A data extraction form was prepared beforehand by the authors to extract relevant data. Information was sourced by two authors independently. Name of the first author, publication year, study type, study location, the definition of elderly, study groups, sample size, demographic details, comorbidity status (cardiovascular disease and diabetes), use of antithrombotic or anticoagulant drugs, ulcer finding, lesion location, lesion depth, histological type, tumor size, lymphatic invasion, and study outcomes were extracted.

The primary outcomes were en-bloc resection rates and histological complete resection rates. En-bloc resection was defined as resection of the tumor in one piece. Histological complete resection was defined as the histological identification of tumor-free margins in the resected tissue. Secondary outcomes were complications namely; incidence of perforation, bleeding, and pneumonia. Complications included both intraoperative and postoperative incidence combined. For the primary outcomes, data were pooled based on the number of lesions while for the secondary outcome, data were pooled based on the number of patients.

The methodological quality of included studies was assessed using the Newcastle-Ottawa scale (NOS) (14). This too was carried out in duplicate and independently by two study investigators. Studies were awarded points for selection of study population, comparability, and outcomes. The maximum score which can be awarded is nine. The certainty of the evidence was assessed using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) tool using the GRADEpro GDT software [GRADEpro Guideline Development Tool. McMaster University, 2020 (developed by Evidence Prime, Inc.)].

Statistical Analysis

Meta-analysis was carried out using "Review Manager" (RevMan, version 5.4; Nordic Cochrane Centre [Cochrane Collaboration], Copenhagen, Denmark; 2014). On account of the inherent heterogeneity amongst the included studies, a random-effects model was used for the meta-analysis of all outcomes. Odds ratios (OR) with 95% confidence intervals (CI) were calculated to compare resection rates and complications between the elderly and non-elderly groups. Mean and standard deviation (SD) data of the length of hospital stay was extracted and pooled to calculate the mean difference (MD) and 95% CI. Heterogeneity was assessed using the I² statistic. I² values of 25-50% represented low, values of 50-75% medium, and more than 75% represented substantial heterogeneity. We used funnel plots to assess publication bias for the primary outcomes. Since the definition of elderly differed across included studies, we carried out a subgroup analysis for the variable definitions. We divided the data into the following three subgroups: ≥80 years vs <80 years, \geq 75 years vs < 75 years, and \geq 65 years vs <65 years. A sensitivity analysis was also performed for a meta-analysis of resection rates and complications. Individual studies were sequentially excluded from the meta-analysis in the software itself to check any undue influence of the study on the total effect size. P \leq 0.05 was considered statistically significant. For analyses with I²<50%, we also checked the results using a fixed-effects model in the metaanalysis software for any change in the significance of the results.

RESULTS

A total of 6382 records were available after the literature search (**Figure 1**). After excluding duplicates, 3294 articles were examined by their titles and abstracts. 3271 studies were not found to be relevant to the review and hence excluded. 23 articles were screened by their full-texts and six (15–20) were excluded with reasons (**Table 1**). Finally, 17 cohort studies were found to be eligible for inclusion in this review (4, 10–12, 21–33).

The data extracted from individual studies are presented in Table 2. All studies, except one (26), were retrospective in nature. The studies were published between 2005 to 2019. The majority of studies were conducted in Japan with just three of the included studies being conducted in China, Taiwan, and South Korea (one each). The definition early gastric cancer and indications of ESD were based mostly on the Japanese Gastric Cancer Association definitions [version 2 (35) or version 3 (36)] or either those defined by Gotoda et al. (34). The definition of the elderly population varied across studies with ≥75 years and <75 years being the most common classification used. Four studies classified the elderly as ≥80 years while one study classified them as ≥ 65 years. In the study of Yamaguchi et al. (27) and Watanabe et al. (4), three subgroups were subsumed to ≥ 80 years vs <80 years and \geq 65 years vs <65 years respectively. The sample size of the elderly group ranged from 32 to 554 while in the nonelderly group it varied from 42 to 21860. None of the included studies carried out propensity score matching of the study groups. The NOS score of the included cohort studies varied from 6 to 8.

Primary Outcomes

En-Bloc Resection


En-bloc resection rates were reported by 14 studies. Data of 2634 lesions in the elderly was compared with data of 3782 lesions in the non-elderly. Meta-analysis indicated no statistically significant difference in the en-bloc resection rates between the two groups (OR: 0.92 95% CI: 0.68, 1.26 $I^2 = 8\%$ p=0.62) (**Figure 2**). The difference was non-significant even on subgroup analysis for \geq 65 years vs <65 years (OR: 1.20 95% CI: 0.57, 2.54 $I^2 = 0\%$ p=0.63), \geq 75 years vs <75 years (OR: 0.88 95% CI: 0.56, 1.39 $I^2 = 29\%$ p=0.58), and \geq 80 years vs <80 years (OR: 0.92 95% CI: 0.46, 1.82 $I^2 = 5\%$ p=0.81). We found no evidence of publication bias on funnel plot (**Supplementary Figure 1**). However, the certainty of evidence was "very low" (**Supplementary Table 2**).

Histological Complete Resection

13 of the 17 studies reported histological complete resection rates. Comparing 2589 lesions in the elderly group with 3702 lesions in the non-elderly group, we found no statistically significant difference in the histological complete resection rates between the two groups (OR: 0.93 95% CI: 0.75, 1.15 $I^2 = 26\% p=0.50$) (**Figure 3**). The difference remained non-significant on subgroup analysis for ≥ 65 years vs <65 years (OR: 0.66 95% CI: 0.33, 1.32 $I^2 = 0\% p=0.24$), ≥ 75 years vs <75 years (OR: 0.98 95% CI: 0.73, 1.32 $I^2 = 42\% p=0.90$), and ≥ 80 years vs <80 years (OR: 0.89 95% CI: 0.75, 1.15 $I^2 = 26\% p=0.50$). There was no publication bias based on assessment of funnel plot (**Supplementary Figure 2**). On GRADE assessment the certainty of evidence was found to be "very low" (**Supplementary Table 2**).

Secondary Outcomes Perforation

All included studies reported perforation rates. On pooled analysis, we found statistically non-significant but tendency of higher perforation rates in the elderly (OR: 1.22 95% CI: 0.99,



1.52 I² = 0% p=0.06) (**Figure 4**). However, on subgroup analysis, there was a significantly increased risk of perforation in elderly patients aged ≥80 years as compared to patients <80 years (OR: 1.50 95% CI: 1.00, 2.24 I² = 3% p=0.05); but no difference in the other subgroups of ≥65 years vs <65 years (OR: 1.71 95% CI: 0.70, 4.18 I² = 0% p=0.24) and ≥75 years vs <75 years (OR: 0.89 95% CI: 0.62, 1.30 I² = 0% p=0.56). However, the certainty of evidence was "very low" (**Supplementary Table 2**).

Bleeding

Bleeding rates were reported by all studies. Meta-analysis demonstrated no statistically significant difference in the

TABLE 1	Details of excluded stu	idies.
---------	-------------------------	--------

Study	Reason for exclusion
Abe 2012 (15)	Not comparing elderly vs non-elderly
Sumiyoshi 2017 (16)	Not comparing elderly vs non-elderly
Sekiguchi 2017 (17)	Not comparing elderly vs non-elderly
Chang 2020 (18)	Not comparing elderly vs non-elderly
Toya 2019 (19)	Overlapping data
Pyo 2017 (20)	Overlapping data

bleeding rates between the two groups (OR: 1.07 95% CI: 0.87, 1.32 $I^2 = 19\%$ p=0.52) (**Figure 5**). The difference was nonsignificant even on subgroup analysis for \geq 65 years vs <65 years (OR: 0.93 95% CI: 0.54, 1.62 $I^2 = 0\%$ p=0.80), \geq 75 years vs < 75 years (OR: 1.19 95% CI: 0.84, 1.68 $I^2 = 33\%$ p=0.34), and \geq 80 years vs <80 years (OR: 0.91 95% CI: 0.76, 1.10 $I^2 = 0\%$ p=0.34). The certainty of evidence was found to be "very low" (**Supplementary Table 2**).

Pneumonia

Data on pneumonia was reported by 13 studies. Pooled analysis indicated a statistically significantly increased risk of pneumonia in elderly patients (OR: 2.52 95% CI: 1.72, 3.70 $I^2 = 7\%$ p<0.00001) (**Figure 6**). The incidence was significantly increased for the subgroup of \geq 75 years vs < 75 years (OR: 3.94 95% CI: 2.09, 7.42 $I^2 = 0\%$ p<0.0001) and \geq 80 years vs <80 years (OR: 2.04 95% CI: 1.12, 3.72 $I^2 = 17\%$ p=0.02) but non-significant albeit with a tendency of increased risk in the elderly for the subgroup of \geq 65 years vs <65 years (OR: 4.16 95% CI: 0.52, 33.01 $I^2 = 0\%$ p=0.18). On GRADE assessment the certainty of evidence was found to be "very low" (**Supplementary Table 2**).

TABLE 2 | Details of included studies.

Author/ Year	Country	Definition of EGC	Groups (years)	Sample size	Mean Age (years)	Male gender (%)	CVS disease (%)	DM (%)	Use of AT/ AC (%)	Ulcer finding (%)	Location U/M/L	Invasion depth IM/SM	Histological type D/UD	Tumor size (mm)	Lymphatic invasion (%)	NOS score
Yamaguchi 2019 (27)	Japan	JGCA version 3	>80	94 (107) ^	83.9	69.1	24.5	NR	33	11.2	22/24/61	96/11	102/5	17.5	8.4	7
			65-79	266 (293)	72.3	71.4	18.8		22.2	9.9	52/82/159	253/40	281/12	15.6	6.5	
			<65	92 (101)	58.1	79.3	5.4		6.5	5	15/27/59	93/8	96/5	13.1	2	
Son 2019	South	JGCA	≥80	32	82.3	53.1	9.4	15.6	18.8	0	5/4/23	NR	32/0	NR	NR	6
(11)	Korea	version NR	<80	406	64.5	64.8	8.4	16.5	18.2	1	23/64/319		404/2			
Okimoto 2019 (10)	Japan	JGCA version 3	≥80	108 (128)^	83.4	75.9	21.3	11.1	27.8	NR	16/35/77	114/14	125/3	16.5	3.9	8
			<80	425 (504)	69.6	72	13.6	10.8	16		87/143/ 274	456/48	489/15	16.5	3.4	
Watanabe	Japan	JGCA	≥85	43 (48)^	86	62.3	21	14	30.2	NR	13/15/20	40/8	46/2	NR	6.3	6
2017 (4)		version 3	65-84	511 (652)	75	68.9	13.3	15.7	24.1		122/272/ 258	564/88	634/18		6.7	
			≤64	161 (177)	60	83.2	10	13.4	11		37/73/67	164/13	170/7		2.3	
Otsuka	Japan	JGCA	≥80	64	84.2	68.7	35.9	31.2	6.3	NR	28/16/20	NR	63/1	17.5	NR	6
2017 (12)		version 3	<80	168	69.5	70.2	14.9	28	7.1		39/55/72		149/9	15.6		
Kato 2016 (26)	Japan	JGCA version 3	≥75	345 (421)^	80	69	11.9	19.4	25.2	13.3	77/210/ 134	386/35	408/13	17.5	NR	8
			<75	547 (641)	65	80.6	4.6	14.3	11.9	14.5	102/332/ 207	572/69	610/31	16.6		
Chinda 2015 (24)	Japan	NR	≥75	102 (109)^	79.2	63.7	21.6	10.8	30.4	NR	NR	NR	NR	23.5	NR	6
			<75	205 (209)	65.9	76.5	10.2	20.5	16.6					20.1		
Yang 2015	Taiwan	JGCA	≥75	44	81.6	81.8	38.6	43.2	11.4	NR	0/28/16	37/7	44/0	22	NR	6
(25)		version 3	<75	42	63.4	69	11.9	26.2	16.7		1/18/23	40/2	41/1	19.5		
Zhang 2014	China	Gotoda et	≥75	46 (51)^	79	71.7	17.4	21.7	8.7	21.6	9/17/25	NR	NR	NR	NR	8
(23)		al. (34)	<75	125 (136)	59.4	63.2	10.4	15.2	4.8	15.4	9/44/83					
Murata 2014 (22)	Japan	NR	≥80	5525	NR	65.5	5.5	12.2	7.7	NR	569/2801/ 2155	NR	NR	NR	NR	6
			<80	21860		76.2	2.8	11.8	4.1		1880/ 12001/ 7979					
Tokioka 2012 (21)	Japan	JGCA version 2	≥65	372	73.9	69.9	7.8	15.3	NR	NR	25/109/ 229	98.6	341/0	15.1	NR	7
			<65	143	57.7	82.5	0.7	6.3			23/45/74	96.5	139/4	14.5		
Toyokawa 2010 (33)	Japan	NR	≥75	200 (229)^	80	64	20	21	5.5	NR	54/76/98	158/28	NR	19	NR	8
			<75	314 (357)	66	75.5	11	15	1.6		93/141/ 122	245/41		18		
lsomoto 2010 (32)	Japan	JGCA version 2	≥75	260 (279)^	NR	72.4	NR	NR	NR	3.7	44/129/ 105	222/57	NR	18	NR	6
			<75		NR	79				13.3		369/65		18		

(Continued)

Author/ Year	Country	Definition of EGC	Groups (years)	Sample size	Mean Age (years)	Male gender (%)	CVS disease (%)	MU (%)	Use of AT/ AC (%)	Ulcer finding (%)	Location U/M/L	Invasion depth IM/SM	Histological type D/UD	Tumor size (mm)	Lymphatic invasion (%)	NOS score
				401							73/209/					
				(434)							149					
Shimura	Japan	Gotoda et	575	41 (45)^	78	80.5	24.4	2.4	19.5	NR	6/25/14	NR	NR	16	NR	7
2007 (28)		al (34)	65-74	41 (45)	70	70.7	12.2	2.4	12.2		7/20/18			15		
			<65	34 (35)	61	82.4	2.9	5.9	5.9		4/16/15			17		
Onozato	Japan	JGCA	575	93	79.8	53.8	NR	ЯN	NR	14.6	18/45/47	102/8	NR	22.8	NR	9
2007 (31)		version 2	<75	133	66	79.7				20.5	25/35/81	114/27		21.8		
Kakushima	Japan	JGCA	575	49	NR	NR	NR	NR	NR	NR	ЯN	NR	NR	NR	NR	9
2007 (29)		version 2	<75	135												
Hirasaki	Japan	JGCA	575	53	78.2	64.2	1.9	9.4	11	NR	ЯN	47/6	NR	12.2	ЯN	9
2005 (30)		version 2	<75	91	64.7	81.3	5.5	14	8.8			83/8		13		

^A figures in parenthesis indicates number of lesions.

antithrombotic; AC, anticoagulant; U, upper; M, middle; L, lower; IM, intranucosat; SM, submucosat; NOS, Newcastle-Ottawa scale; D, differentiated; UD, undifferentiated; NR, cardiovascular disease; DM, diabetes mellitus; AT, Japanese Gastric Cancer Association reported; JGCA, CVS,

not

ESD for Gastric Cancer

Length of Hospital Stay

Length of hospital stay was reported as mean and standard deviation only by five studies. Meta-analysis indicated no significant difference between the two study groups (MD: 0.67 95% CI: -0.14, 1.48 I² = 83% p=0.10) (Figure 7). The certainty of evidence was found to be "very low" (Supplementary Table 2).

Sensitivity Analysis

On the sequential exclusion of individual studies from the metaanalysis of resection rates and complications, we found no change in the direction of the result for any outcomes. All results were stable and maintained the significance of the overall effect. For all analyses with $I^2 < 50\%$, we also checked the pooled effect size using a fixed-effects model. However, there was no change in significance of any of the results (data not shown).


DISCUSSION

The elderly population is known to be at higher risk of cancer with most solid tumors being associated with older age. Data from the western population indicates that almost one-third of new cancer cases are detected in patients aged >75years and this figure may treble by 2040 (37, 38). Similarly, age is an important factor in the epidemiology of gastric cancer with tumors frequently detected in the elderly population (39). Guidelines for the management of gastric cancer are frequently derived from clinical trials conducted in a younger population with most studies excluding patients aged >75 years (40). In this context, it is important to differentiate the applicability and complications associated with gastric cancer treatment in this cohort of patients.

ESD has more or less replaced endoscopic submucosal resection (ESR) for the treatment of early malignancies of the gastrointestinal tract. ESR had technical limitations as lesions >15mm were prone to recurrence due to incomplete resection of the tumor (41). Studies have shown that ESD improves en-bloc and complete resection rates as compared to ESR but with a higher risk of complications due to technical challenges of the procedure (42). Since many physiological changes occur with increasing age including deterioration of organ function and changes in body composition, it is important to understand the efficacy of ESD for elderly patients (40).


For the primary outcomes of en-bloc resection rates and histological complete resection rates, our meta-analysis found no statistically significant difference between elderly and younger patients. Our results concur with the previous meta-analysis of Lin et al. (9) which also reported no statistically significant difference in en-bloc resection rates (OR: 0.98 95% CI: 0.56, 1.71) and histological complete resection rates (OR: 0.79 95% CI: 0.58, 1.07) between the two groups, albeit with an analysis of only six studies and a maximum sample size of 2146 patients. The current review was able to include up to 14 studies with a maximum sample of 6416 patients thereby significantly strengthening the validity of the results. Another important strength of our study was that we were able to differentiate between various subgroups of the elderly. The criteria for

FABLE 2 | Continued



defining the elderly are known to differ in literature (43). Our analysis indicates that ESD can be carried out even in the "superelderly" group of \geq 80 years without any impact on en-bloc or histological complete resection rates. These rates are important as they are considered to be indicators to measure the oncological adequacy of ESD (36). However, our review was unable to decipher the long-term clinical outcomes of ESD in the elderly for want of data. In one of the included studies, Okimoto et al. (10) did not find any significant difference between overall survival and disease free-survival between patients aged \geq 80 vs <80 years of age. On the other hand, Watanabe et al. (4) have reported higher mortality with early gastric cancer in the very

c	Elder		Non-ele			Odds Ratio		Odds Ratio
Study or Subgroup 1.2.1 ≥65 vs <65	Events	Total	Events	Total	Weight	IV, Random, 95% CI	Year	IV, Random, 95% CI
	2.65				2 201			
Tokioka 2012		372	140	143	2.3%	1.12 [0.28, 4.38]		
Watanabe 2017 Subtotal (95% CI)	651	700 1072	170	177 320	5.8% 8.1%	0.55 [0.24, 1.23] 0.66 [0.33, 1.32]	2017	
Total events	1016	1072	310	320	0.1/0	0.00 [0.55, 1.52]		
Heterogeneity: Tau ²		u2 - 0		1 (B - 0	2 9), 12 -	0%		
Test for overall effect				I (F = 0	.56), 1 =	0%		
1.2.2 ≥75 vs <75								
Hirasaki 2005	41	53	75	91	5.4%	0.73 [0.31, 1.69]	2005	
Isomoto 2010	204	279	346	434	17.3%	0.69 [0.49, 0.98]	2010	
Toyokawa 2010	183		293	357	14.4%	0.87 [0.57, 1.32]		
Zhang 2014	49	51	131	136	1.6%	0.94 [0.18, 4.98]		
Chinda 2015	95	109	167	209	8.1%	1.71 [0.89, 3.29]		
Yang 2015	33	44	33	42	4.0%	0.82 [0.30, 2.23]		
Kato 2016 Subtotal (95% CI)		421 1186	564	641 1910	14.7% 65.5%	1.42 [0.94, 2.14] 0.98 [0.73, 1.32]	2016	↓
Total events	989		1609					
Heterogeneity: Tau ²				6 (P =	0.11); I ² =	= 42%		
Test for overall effect	z = 0.13	P = 0	.90)					
$1.2.3 \ge 80 \text{ vs} < 80$								
Otsuka 2017	61	64	168	168	0.5%	0.05 [0.00, 1.02]		• • • • • • • • • • • • • • • • • • •
Yamaguchi 2019	63	107	234	394	13.9%	0.98 [0.63, 1.51]		+
Okimoto 2019	110		432	504	10.2%	1.02 [0.58, 1.78]		+
Son 2019	30	32	391	406	1.9%	0.58 [0.13, 2.63]	2019	
Subtotal (95% CI)		331		1472	26.5%	0.89 [0.56, 1.41]		-
Total events	264		1225		252 12	2.70/		
Heterogeneity: Tau ² Test for overall effect				5 (P = 0)	.25); 1° =	27%		
rescrot overall effect	2 = 0.30		.01)					
Total (95% CI)		2589		3702	100.0%	0.93 [0.75, 1.15]		
Total events	2269		3144					
Heterogeneity: Tau ²	= 0.04; Cl	$ni^2 = 16$.33, df =	12 (P =	= 0.18); I ²	= 26%	F	0.01 0.1 1 10 10
Test for overall effect							C C	Favours [Elderly] Favours [Non-elderly]
Test for subgroup dif	fferences:	Chi ² =	1.08, df	= 2 (P =	0.58), I ²	= 0%		ravours [Elacity] Tavours [Non-eldeny]



	Elde		Non-e			Odds Ratio		Odds Ratio
Study or Subgrou	p Events	Total	Events	Total	Weight	IV, Random, 95% CI	Year	IV, Random, 95% Cl
1.3.1 ≥65 vs <65								
Tokioka 2012		372	4	143	3.6%	1.36 [0.44, 4.20]		
Watanabe 2017	17		2	161	2.1%	2.52 [0.58, 11.01]	2017	
Subtotal (95% CI)		926		304	5.7%	1.71 [0.70, 4.18]		•
Total events	31		6					
Heterogeneity: Tau				1 (P = 0	.52); I ² =	0%		
Test for overall eff	ect: $Z = 1.1$	7 (P = 0)).24)					
1.3.2 ≥75 vs <75								
Hirasaki 2005	1		1	91	0.6%	1.73 [0.11, 28.26]		
Onozato 2007	3		6	133	2.3%	0.71 [0.17, 2.90]		
Shimura 2007	1		3	75	0.9%	0.60 [0.06, 5.96]		
Kakushima 2007	1		5	135	1.0%	0.54 [0.06, 4.76]		
Toyokawa 2010	4		14	314	3.6%	0.44 [0.14, 1.35]		
Isomoto 2010	7		11	401	5.0%	0.98 [0.38, 2.56]		
Zhang 2014	1		5	125	1.0%	0.53 [0.06, 4.69]		
Yang 2015	1	44	1	42	0.6%	0.95 [0.06, 15.75]		
Chinda 2015	2		7	205	1.8%	0.57 [0.12, 2.77]		
Kato 2016	25		34	547	16.1%	1.18 [0.69, 2.01]		_ _
Subtotal (95% CI)		1233		2068	32.9%	0.89 [0.62, 1.30]		•
Total events	46		87					
Heterogeneity: Tau				9 (P = 0	.92); I ² =	0%		
Test for overall eff	ect: Z = 0.5	8 (P = 0).56)					
1.3.3 ≥ 80 vs <80								
Murata 2014		5525	107	21860	F.0. C0/	1.33 [1.00, 1.76]	2014	_
Otsuka 2017	1		197	168	58.6%	7.96 [0.32, 197.97]		
Okimoto 2019	0		1	425	0.4%			
						1.30 [0.05, 32.24]		
Son 2019	0		1	406	0.4% 1.4%			
Yamaguchi 2019 Subtotal (95% CI)	5	5823	2	358 23217	1.4% 61.4%	5.87 [0.97, 35.64] 1.50 [1.00, 2.24]	2019	
Total events	70		201	23217	01.4/0	1.50 [1.00, 2.24]		
Heterogeneity: Tau				4 (D - 0	201118 -	20/		
Test for overall eff				4(P = 0	59), 1 =	3%		
Test for overall en	ect. z = 1.9	5 (F = C	.05)					
Total (95% CI)		7982		25589	100.0%	1.22 [0.99, 1.52]		
Total events	147		294					ľ
Heterogeneity: Tau				= 16 (P -	0 71) 12	= 0%		
Test for overall eff				- 10 (F -	0.7 1), 1	- 0/0		0.005 0.1 1 10 200
Test for subgroup				= 2 (P -	0 13) 12	= 50.9%		Favours [Elderly] Favours [Non-elderly]
rescror subgroup	uniciences.		4.07, ui	- 2 (F =	0.13), 1	- 50.5%		

elderly (\geq 85 years) and elderly (65-84 years) as compared to nonelderly patients. In addition to the contradictory results, at this point, it is also unclear if the overall survival is affected by differences in the clinicopathological characteristics of gastric cancer in the elderly group or if the higher comorbidity status plays a major role in influencing survival (40). Only further studies comparing elderly and non-elderly patients and assessing long-term survival can provide clarity on this subject.


	Eld	erly	Non-e	Iderly		Odds Ratio			Odds Ratio	
Study or Subg		s Total	Events	Total	Weight	IV, Random, 95% CI	Year	IN	V, Random, 95% Cl	
1.4.1 ≥65 vs	<65									
Tokioka 2012	1	9 372	7	143	4.8%	1.05 [0.43, 2.54]	2012			
Watanabe 201	7 3	3 554	11	161	7.1%	0.86 [0.43, 1.75]	2017			
Subtotal (95%	S CI)	926		304	11.9%	0.93 [0.54, 1.62]			-	
Total events	5	2	18							
Heterogeneity:	: Tau ² = 0.00;	$Chi^2 = 0$.11, df =	1 (P = 0	.74); I ² =	0%				
Test for overal	Il effect: Z = 0	26 (P =	0.80)							
1.4.2 ≥75 vs ·	<75									
Hirasaki 2005	2	3 53	39	91	7.5%	1.02 [0.52, 2.03]	2005		_ _	
Kakushima 20	07	3 49	4	135	1.8%	2.14 [0.46, 9.91]	2007			
Onozato 2007		6 93	16	133	4.1%	0.50 [0.19, 1.34]		-		
Shimura 2007		6 41		75	3.4%	1.11 [0.37, 3.32]				
Isomoto 2010		4 260		401	6.5%	1.46 [0.69, 3.09]				
Toyokawa 201				314	8.3%	1.92 [1.01, 3.64]				
Zhang 2014		1 46		125	4.8%	2.71 [1.11, 6.58]				
Chinda 2015		6 102			3.8%	1.10 [0.40, 3.07]				
Yang 2015		1 44		42	0.9%	0.22 [0.02, 2.06]				
Kato 2016	1			547	7.6%	0.75 [0.38, 1.48]				
Subtotal (95%		3 345 1233		2068	48.5%	1.19 [0.84, 1.68]	2016			
Total events				2008	40.3%	1.19 [0.84, 1.08]				
Heterogeneity:	10		158	0 (0	0.152.12	2.24				
Test for overal				= 9 (P =	0.15); 1- =	= 33%				
rest for overal	f = 0	95 (P =	0.54)							
1.4.3 ≥ 80 vs	< 80									
Murata 2014		7 5525	568	21860	27.6%	0.88 [0.73, 1.07]	2014		-	
Otsuka 2017		1 64		168	1.0%	0.32 [0.04, 2.59]				
Okimoto 2019		7 108		425	4.7%	1.57 [0.64, 3.85]				
Son 2019		2 32		423	1.8%	1.87 [0.41, 8.60]				
		2 52 6 94			4.4%					
Yamaguchi 20 Subtotal (95%		5823	21	358 23217	4.4% 39.5%	1.09 [0.43, 2.79] 0.91 [0.76, 1.10]	2019			
			620	23217	39.3%	0.91 [0.76, 1.10]			T	
Total events	14		629		102 12					
Heterogeneity				4 (P = 0	.48); 1* =	0%				
Test for overal	Il effect: $Z = 0$	96 (P =	0.34)							
Total (95% CI)	、 、	7982		25590	100.0%	1.07 [0.87, 1.32]			L	
				20089	100.0%	1.07 [0.87, 1.32]			T	
Total events	30		805							
Heterogeneity				= 16 (P =	= 0.24); l ²	= 19%		0.01 0.1	1 10	100
Test for overal									[Elderly] Favours [Non-elderl	
Test for subgr	oup difference	s: Chi ² =	1.68, df	= 2 (P =	: 0.43), l ²	= 0%				

	Elder		Non-el			Odds Ratio		Odds Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	IV, Random, 95% CI	Year	r IV, Random, 95% CI	
1.5.1 ≥65 vs <65									
Tokioka 2012		372	0	143	1.6%	1.94 [0.09, 40.58]			-
Watanabe 2017	13	554	0	161	1.8%		2017		
Subtotal (95% CI)		926		304	3.3%	4.16 [0.52, 33.01]			
Total events	15		0						
Heterogeneity: Tau ²				1 (P = 0)	50); I ² =	0%			
Test for overall effe	t: $Z = 1.35$	5 (P = 0)	.18)						
1.5.2 ≥75 vs <75									
Kakushima 2007	0	49	0	135		Not estimable	2007	,	
Shimura 2007	1		2	75	2.4%				
Isomoto 2010	6	260	0	401		20.51 [1.15, 365.61]			→
Toyokawa 2010	2	200	1	314	2.5%				
Chinda 2015	0	102	1	205	1.4%				
Yang 2015	3	44	0	42	1.6%	7.17 [0.36, 143.11]	2015		→
Kato 2016	26	345	10	547	21.1%	4.38 [2.08, 9.20]	2016		
Subtotal (95% CI)		1041		1719	30.7%	3.94 [2.09, 7.42]			
Total events	38		14						
Heterogeneity: Tau ²				5 (P = 0)	54); I ² =	0%			
Test for overall effe	t: $Z = 4.23$	3 (P < 0	.0001)						
1.5.3 ≥ 80 vs <80									
Murata 2014	44	5525	87	21860	53.5%	2.01 [1.40, 2.89]	2014	· · · · · · · · · · · · · · · · · · ·	
Okimoto 2019	4	108	11	425	9.7%				
Son 2019	1	32	0	406	1.4%	38.71 [1.55, 969.98]	2019)	. →
Yamaguchi 2019	0		1	358	1.4%				
Subtotal (95% CI)		5759		23049	66.0%	2.04 [1.12, 3.72]		◆	
Total events	49		99						
Heterogeneity: Tau ²				3 (P = 0)	.30); I ² =	17%			
Test for overall effe	t: $Z = 2.32$	2 (P = 0)	.02)						
Total (95% CI)		7726		25072	100.0%	2.52 [1.72, 3.70]			
Total events	102		113	23072	100.070	2.52 [2.72, 5.70]		•	
Heterogeneity: Tau ²		$ni^2 = 11$		11 (P =	0.38): 12	= 7%		L	
Test for overall effe					0.50), 1	- 776		0.01 0.1 i 10	100
Test for subgroup d				= 2 (P =	$0.32)$ l^2	= 13.4%		Favours [Elderly] Favours [Non-elderly	1
i cot i or babgi cap a		0		- (.	0.54/, 1	2011/0			

Despite the minimally invasive nature of ESD, procedurerelated adverse events are common especially perforation, bleeding, and pneumonia. The rates of perforation are known to vary from 1.2 to 9.6% with ESD for early gastric cancer (9, 44). In our review, we noted a perforation rate of 1.84% for the elderly group which was within the range described in the literature. Overall, the risk of perforation was not significantly higher but considering the 95% CI with the lower limit close to 1, there was a tendency of increased perforation rates in the elderly. Also, on subgroup analysis, we noted a 1.5 times increased risk of perforation in the super-elderly group of ≥80 years. Important to note is that many factors can influence perforation rates. A recent study by Ding et al. (44) has demonstrated that liver disease, upper location of the lesion, larger tumor size, submucosal invasion, longer operating time, gross lesion type, and piecemeal resection significantly affect perforation rates. Since the two cohorts in our study were not matched for baseline characteristics these factors may have influenced the outcome.

The number of comorbidities is known to increase with age many of which require anti-thrombotic and anticoagulant prophylaxis. While there has been no consensus on the effects of these drugs on bleeding rates with ESD, a recent meta-analysis suggests that regardless of continuation or discontinuation, antithrombotic drugs significantly increase the risk of delayed bleeding with ESD (45). Other lesion-related factors like lesion size, location on the lesser curvature, lesion morphology, histology, and ulcer finding also affect bleeding rates (46). In our review, we found no significant difference in the risk of bleeding with ESD between elderly and non-elderly patients. The non-significant results were noted even in the super elderly group of \geq 80 years.

Elderly patients are prone to respiratory complications like pneumonia owing to the higher number of comorbidities and poor immune status. Indeed, a recent study has indicated that the Charlson comorbidity index of ≥ 3 is associated with an increased risk of respiratory-related complications in elderly patients undergoing ESD for early gastric cancer (47). Furthermore, lowered ability to expectorate post-procedure may also contribute to aspirational pneumonia. It is suggested that adequate suction may reduce the incidence of aspiration with ESD (9). In our analysis, we noted an increased risk of



pneumonia in elderly patients irrespective of the cut-off age. The results were statistically non-significant for the subgroup of ≥ 65 vs <65 probably due to the limited number of studies in this analysis. But considering the 95% CI with an upper limit of 33, it is plausible that the risk of pneumonia is increased even with an age of ≥ 65 years.

The limitations of our review need to be specified. Foremost, it is important to note that all of the outcome variables can be influenced by several confounding factors. In the absence of baseline matching or multivariable-adjusted outcomes, the effect of several known and unknown confounding factors on the review outcomes cannot be negated. Since all included studies in the review were retrospective cohort in nature with inherent selection bias, the results should be interpreted with caution. On GRADE assessment of the outcomes, we found that the certainty of evidence was "very low" for all included outcomes. Secondly, the definition of elderly was not coherent in the included studies. While we attempted a subgroup analysis to better elucidate this difference, the variable definitions could have skewed the overall outcome. Thirdly, our review could not assess survival outcomes due to the non-availability of data. Long-term survival outcomes were reported only by Isomoto et al. (32), Okimoto et al. (10), and Watanabe et al. (4) wherein the elderly were defined as >75 years; >80 years and >65 years respectively. Considering the limited number of studies reporting the outcome with different definition of elderly, it was not feasible to conduct any pooled analysis for the outcome. Furthermore, such an analysis would have been biased, as it would include data of just three out of 17 studies. Fourthly, the majority of the studies included in our review were from a single country. The remaining studies too were from east Asia. This significantly limits the applicability of our results to western populations. Lastly, the definition of early gastric cancer and the indication for ESD did vary amongst the included studies. It needs to be highlighted that definition of early gastric cancer has broadened with time with Barreto et al. (48) now defining it as "An early gastric cancer is one that infiltrates the mucosa of the stomach without lymph node metastases. On biopsy or endoscopic specimen an early gastric cancer is <2 cm in maximum diameter, well differentiated, intestinal type, nonulcerated, not depressed, located in the proximal stomach, and without infiltration beyond the mucosal layer or evidence of lympho-vascular invasion. On the surgical specimen an early gastric cancer is also without evidence on lymph node metastases from at least a D1 lymphadenectomy". Future studies should use the expanded definition in order to present better evidence.

Despite these limitations, our review provides a comprehensive comparison of outcomes of ESD between elderly and non-elderly

REFERENCES

- United Nations, Department of Economic and Social Affairs, Population Division. World Population Ageing 2019 (ST/ESA/SER.A/444). (2020). Available at: www.unpopulation.org (Accessed on 01 May 2021).
- Rawla P, Barsouk A. Epidemiology of Gastric Cancer: Global Trends, Risk Factors and Prevention. Prz Gastroenterol (2019) 14:26–38. doi: 10.5114/pg.2018.80001
- Fock KM. Review Article: The Epidemiology and Prevention of Gastric Cancer. Aliment Pharmacol Ther (2014) 40:250–60. doi: 10.1111/apt.12814

patients by pooling data from a large number of studies. Considering the small number of complications in individual studies, the meta-analysis provides pooled data with a significantly higher statistical power thereby strengthening the validity of the conclusions. The stability of the results on sensitivity analysis also lends support to the credibility of our results. Unlike the previous review (9), our study was also able to assess ESD outcomes in super-elderly patients. We believe the results of our study shall enable clinicians to make informed decisions and better anticipate outcomes in elderly and super-elderly patients with early gastric cancer.

To conclude, our study indicates that en-bloc and histological complete resection rates do not differ between elderly and nonelderly patients undergoing ESD for early gastric cancer. Elderly patients have a small tendency of increased risk of perforation with significantly increased rates in the super-elderly (\geq 80 years of age). The risk of pneumonia is significantly higher in elderly patients but the rates of bleeding do not differ. The certainty of evidence is "very low" and there is a need for high-quality studies taking into account confounding factors to enhance the quality of evidence.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

AUTHOR CONTRIBUTIONS

JZ, ZS, and JL conceived and designed the study. JZ, ZS, and SG did literature search. JL and DH analyzed the data. JZ, ZS, and DH wrote the paper. JL and SG reviewed and edited the manuscript. All authors read and approved the final manuscript.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2021.718684/ full#supplementary-material

Supplementary Figure 1 | Funnel plot of the meta-analysis of en-bloc resection rates between elderly and non-elderly patients.

Supplementary Figure 2 | Funnel plot of the meta-analysis of histological complete resection rates between elderly and non-elderly patients.

- Watanabe K, Hikichi T, Nakamura J, Takagi T, Suzuki R, Sugimoto M, et al. Endoscopic Submucosal Dissection for Early Gastric Cancer in Very Elderly Patients Age 85 or Older. *Endosc Int Open* (2017) 05:E17–24. doi: 10.1055/s-0042-122960
- Kim Y, Kuan JY, Ratcliffe E, Baskind S, Prasad N, Assadsangabi A, et al. Long-Term Follow-Up of Endoscopic Submucosal Dissection of Gastric Dysplasia and Early Neoplasia in a United Kingdom Caucasian Population–A Tertiary Centre Experience. *Scand J Gastroenterol* (2020) 55:18–26. doi: 10.1080/ 00365521.2019.1707865

- An L, Gaowa S, Cheng H, Hou M. Long-Term Outcomes Comparison of Endoscopic Resection With Gastrectomy for Treatment of Early Gastric Cancer: A Systematic Review and Meta-Analysis. *Front Oncol* (2019) 9:725. doi: 10.3389/fonc.2019.00725
- Draganov PV, Wang AY, Othman MO, Fukami N. AGA Institute Clinical Practice Update: Endoscopic Submucosal Dissection in the United States. Clin Gastroenterol Hepatol (2019) 17:16–25.e1. doi: 10.1016/ j.cgh.2018.07.041
- Li H, Feng LQ, Bian YY, Yang LL, Liu DX, Huo ZB, et al. Comparison of Endoscopic Submucosal Dissection With Surgical Gastrectomy for Early Gastric Cancer: An Updated Meta-Analysis. World J Gastrointest Oncol (2019) 11:161–72. doi: 10.4251/wjgo.v11.i2.161
- Lin Jp, Zhang Yp, Xue M, Chen Sj, Si Jm. Endoscopic Submucosal Dissection for Early Gastric Cancer in Elderly Patients: A Meta-Analysis. World J Surg Oncol (2015) 13:293. doi: 10.1186/s12957-015-0705-4
- Okimoto K, Arai M, Ishigami H, Taida T, Saito K, Maruoka D, et al. Renal Dysfunction is a Risk Factor of Death After Gastric Endoscopic Submucosal Dissection in Elderly Patients Aged ≥80 Years. Can J Gastroenterol Hepatol (2019) 2019:7145182. doi: 10.1155/2019/7145182
- Son YW, Kim A, Jeon HH. Efficacy and Safety of Endoscopic Submucosal Dissection for Gastric Epithelial Neoplasia in Elderly Patients Aged 80 Years and Older. Aging Clin Exp Res (2019) 31:1833–8. doi: 10.1007/s40520-019-01133-6
- Otsuka Y, Akahoshi K, Yasunaga K, Kubokawa M, Gibo J, Osada S, et al. Clinical Outcomes of Clutch Cutter Endoscopic Submucosal Dissection for Older Patients With Early Gastric Cancer. World J Gastrointest Oncol (2017) 9:416–22. doi: 10.4251/wjgo.v9.i10.416
- Moher D, Liberati A, Tetzlaff J, Altman DG. PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. *PloS Med* (2009) 6:e1000097. doi: 10.1371/journal.pmed.1000097
- Wells G, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses. Available at: http://www.ohri.ca/programs/clinical_ epidemiology/oxford.asp (Accessed October 30, 2020).
- Abe N, Gotoda T, Hirasawa T, Hoteya S, Ishido K, Ida Y, et al. Multicenter Study of the Long-Term Outcomes of Endoscopic Submucosal Dissection for Early Gastric Cancer in Patients 80 Years of Age or Older. *Gastric Cancer* (2012) 15:70–5. doi: 10.1007/S10120-011-0067-8
- Sumiyoshi T, Kondo H, Fujii R, Minagawa T, Fujie S, Kimura T, et al. Shortand Long-Term Outcomes of Endoscopic Submucosal Dissection for Early Gastric Cancer in Elderly Patients Aged 75 Years and Older. *Gastric Cancer* (2017) 20:489–95. doi: 10.1007/S10120-016-0628-Y
- Sekiguchi M, Oda I, Suzuki H, Abe S, Nonaka S, Yoshinaga S, et al. Clinical Outcomes and Prognostic Factors in Gastric Cancer Patients Aged ≥85 Years Undergoing Endoscopic Submucosal Dissection. *Gastrointest Endosc* (2017) 85:963–72. doi: 10.1016/J.GIE.2016.10.013
- Chang JW, Jung DH, Park JC, Shin SK, Lee SK, Lee YC. Long-Term Outcomes and Prognostic Factors of Endoscopic Submucosal Dissection for Early Gastric Cancer in Patients Aged ≥75 Years. *Cancers (Basel)* (2020) 12:1–14. doi: 10.3390/CANCERS12113222
- Toya Y, Endo M, Nakamura S, Akasaka R, Yanai S, Kawasaki K, et al. Long-Term Outcomes and Prognostic Factors With non-Curative Endoscopic Submucosal Dissection for Gastric Cancer in Elderly Patients Aged ≥ 75 Years. *Gastric Cancer* (2019) 22:838–44. doi: 10.1007/S10120-018-00913-9
- Pyo JH, Lee H, Min BH, Lee JH, Kim KM, Yoo H, et al. Comparison of Long-Term Outcomes After Non-Curative Endoscopic Resection in Older Patients With Early Gastric Cancer. Ann Surg Oncol (2017) 24:2624–31. doi: 10.1245/S10434-017-5888-1
- Tokioka S, Umegaki E, Murano M, Takeuchi N, Takeuchi T, Kawakami K, et al. Utility and Problems of Endoscopic Submucosal Dissection for Early Gastric Cancer in Elderly Patients. J Gastroenterol Hepatol (2012) 27:63–9. doi: 10.1111/j.1440-1746.2012.07075.x
- 22. Murata A, Muramatsu K, Ichimiya Y, Kubo T, Fujino Y, Matsuda S. Endoscopic Submucosal Dissection for Gastric Cancer in Elderly Japanese Patients: An Observational Study of Financial Costs of Treatment Based on a National Administrative Database. J Dig Dis (2014) 15:62–70. doi: 10.1111/ 1751-2980.12106

- Zhang Y, Huang L, Li L, Ji F. Endoscopic Submucosal Dissection for Early Gastric Neoplasms in Elderly Patients. J Laparoendosc Adv Surg Tech (2014) 24:391–8. doi: 10.1089/lap.2013.0572
- 24. Chinda D, Sasaki Y, Tatsuta T, Tsushima K, Wada T, Shimoyama T, et al. Perioperative Complications of Endoscopic Submucosal Dissection for Early Gastric Cancer in Elderly Japanese Patients 75 Years of Age or Older. *Intern Med* (2015) 54:267–72. doi: 10.2169/internalmedicine.54.3300
- Yang TC, Hou MC, Chen PH, Hsin IF, Chen LK, Tsou MY, et al. Clinical Outcomes and Complications of Endoscopic Submucosal Dissection for Superficial Gastric Neoplasms in the Elderly. *Med (United States)* (2015) 94: e1964. doi: 10.1097/MD.00000000001964
- 26. Kato M, Michida T, Kusakabe A, Sakai A, Hibino C, Kato M, et al. Safety and Short-Term Outcomes of Endoscopic Submucosal Dissection for Early Gastric Cancer in Elderly Patients. *Endosc Int Open* (2016) 04:E521–6. doi: 10.1055/s-0042-102650
- Yamaguchi H, Fukuzawa M, Kawai T, Matsumoto T, Suguro M, Uchida K, et al. Impact of Gastric Endoscopic Submucosal Dissection in Elderly Patients: The Latest Single Center Large Cohort Study With a Review of the Literature. *Med (Baltimore)* (2019) 98:e14842. doi: 10.1097/MD.000000000014842
- Shimura T, Joh T, Sasaki M, Kataoka H, Tanida S, Ogasawara N, et al. Endoscopic Submucosal Dissection is Useful and Safe for Intramucosal Gastric Neoplasms in the Elderly. Acta Gastroenterol Belg (2007) 70:323–30.
- Kakushima N, Fujishiro M, Kodashima S, Muraki Y, Tateishi A, Yahagi N, et al. Technical Feasibility of Endoscopic Submucosal Dissection for Gastric Neoplasms in the Elderly Japanese Population. J Gastroenterol Hepatol (2007) 22:311–4. doi: 10.1111/j.1440-1746.2006.04563.x
- Hirasaki S, Tanimizu M, Nasu J, Shinji T, Koide N. Treatment of Elderly Patients With Early Gastric Cancer by Endoscopic Submucosal Dissection Using an Insulated-Tip Diathermic Knife. *Intern Med* (2005) 44:1033–8. doi: 10.2169/internalmedicine.44.1033
- Onozato Y, Kakizaki S, Ishihara H, Iizuka H, Sohara N, Okamura S, et al. Feasibility of Endoscopic Submucosal Dissection for Elderly Patients With Early Gastric Cancers and Adenomas. *Dig Endosc* (2008) 20:12–6. doi: 10.1111/j.1443-1661.2007.00763.x
- 32. Isomoto H, Ohnita K, Yamaguchi N, Fukuda E, Ikeda K, Nishiyama H, et al. Clinical Outcomes of Endoscopic Submucosal Dissection in Elderly Patients With Early Gastric Cancer. *Eur J Gastroenterol Hepatol* (2010) 22:311–7. doi: 10.1097/MEG.0b013e32832c61d7
- Toyokawa T, Fujita I, Morikawa T, Okamoto A, Miyasaka R, Watanabe K, et al. Clinical Outcomes of ESD for Early Gastric Neoplasms in Elderly Patients. *Eur J Clin Invest* (2011) 41:474–8. doi: 10.1111/j.1365-2362.2010.02428.x
- 34. Gotoda T, Yanagisawa A, Sasako M, Ono H, Nakanishi Y, Shimoda T, et al. Incidence of Lymph Node Metastasis From Early Gastric Cancer: Estimation With a Large Number of Cases at Two Large Centers. *Gastric Cancer* (2000) 3:219–25. doi: 10.1007/pl00011720
- None JGCA. Japanese Classification of Gastric Carcinoma 2nd English Edition -. Gastric Cancer (1998) 1:10–24. doi: 10.1007/S101209800016
- Japanese Gastric Cancer Association JGC. Japanese Gastric Cancer Treatment Guidelines 2014 (Ver. 4). Gastric Cancer (2017) 20:1–19. doi: 10.1007/s10120-016-0622-4
- Maddams J, Utley M, Møller H. Projections of Cancer Prevalence in the United Kingdom, 2010-2040. Br J Cancer (2012) 107:1195–202. doi: 10.1038/ bjc.2012.366
- DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, et al. Cancer Treatment and Survivorship Statistics, 2014. CA Cancer J Clin (2014) 64:252–71. doi: 10.3322/caac.21235
- Charvat H, Sasazuki S, Inoue M, Iwasaki M, Sawada N, Shimazu T, et al. Prediction of the 10-Year Probability of Gastric Cancer Occurrence in the Japanese Population: The JPHC Study Cohort II. *Int J Cancer* (2016) 138:320– 31. doi: 10.1002/ijc.29705
- Joharatnam-Hogan N, Shiu KK, Khan K. Challenges in the Treatment of Gastric Cancer in the Older Patient. *Cancer Treat Rev* (2020) 85:101980. doi: 10.1016/j.ctrv.2020.101980
- Facciorusso A. Endoscopic Submucosal Dissection vs Endoscopic Mucosal Resection for Early Gastric Cancer: A Meta-Analysis. World J Gastrointest Endosc (2014) 6:555. doi: 10.4253/wjge.v6.i11.555
- 42. Tao M, Zhou X, Hu M, Pan J. Endoscopic Submucosal Dissection Versus Endoscopic Mucosal Resection for Patients With Early Gastric Cancer:

A Meta-Analysis. BMJ Open (2019) 9:e025803. doi: 10.1136/bmjopen-2018-025803

- Singh S, Bajorek B. Defining "Elderly" in Clinical Practice Guidelines for Pharmacotherapy. *Pharm Pract* (2014) 12:0–0. doi: 10.4321/s1886-36552014000400007
- Ding X, Luo H, Duan H. Risk Factors for Perforation of Gastric Endoscopic Submucosal Dissection: A Systematic Review and Meta-Analysis. *Eur J Gastroenterol Hepatol* (2019) 31:1481–8. doi: 10.1097/MEG.000000000001543
- Dong J, Wei K, Deng J, Zhou X, Huang X, Deng MM, et al. Effects of Antithrombotic Therapy on Bleeding After Endoscopic Submucosal Dissection. *Gastrointest Endosc* (2017) 86:807–16. doi: 10.1016/j.gie.2017.07.017
- 46. Libânio D, Costa MN, Pimentel-Nunes P, Dinis-Ribeiro M. Risk Factors for Bleeding After Gastric Endoscopic Submucosal Dissection: A Systematic Review and Meta-Analysis. *Gastrointest Endosc* (2016) 84:572–86. doi: 10.1016/ j.gie.2016.06.033
- 47. Kim S, Kim DH, Park SY, Park CH, Kim HS, Choi SK, et al. Association Between Charlson Comorbidity Index and Complications of Endoscopic Resection of Gastric Neoplasms in Elderly Patients. *BMC Gastroenterol* (2020) 20:213. doi: 10.1186/s12876-020-01360-6

 Barreto SG, Windsor JA. Redefining Early Gastric Cancer. Surg Endosc (2016) 30:24–37. doi: 10.1007/s00464-015-4184-z

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Zhao, Sun, Liang, Guo and Huang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.